About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Blue Light Phototherapy | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT04343586

Blue Light Phototherapy

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

Lead sponsor: Northwestern University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Northwestern University

Collaborators

T-Cellerate LLC

Age

18 - 89 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patient's aged 18-89 at time of enrollment
•2. Previous diagnosis of psoriasis vulgaris or Grover's disease

Exclusion Criteria

•1. All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
•2. Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
•3. Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
•* topical steroids
•* calcineurin inhibitors
•* methotrexate
•* retinoids
•* biologic agents
•4. Unable to schedule phototherapy sessions
•5. We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

Related studies

RECRUITINGPhase 4

Proactive TDM Versus Standard Use of Biologics in Psoriasis

NCT06398106 · Psoriasis Vulgaris

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

NCT07320872 · Psoriasis Vulgaris

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635 · Psoriasis Vulgaris

COMPLETEDPhase 4

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

NCT04306315 · Psoriasis Vulgaris

COMPLETEDPhase 4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076 · Psoriasis, Psoriasis Vulgaris

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment11

Start dateSep 2020

Last updatedMar 17, 2023

Condition

Grover's Disease Psoriasis Vulgaris

Locations shown

Northwestern University Department of Dermatology

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions